Invivo Partners

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

Founded in 2020, NEUmiRNA focuses on achieving transformative disease modification for neurological conditions.

Gyala Therapeutics specializes in developing innovative CAR-T therapies aimed at treating hematological malignancies. CAR-T (chimeric antigen receptor T cell) therapy involves extracting T lymphocytes from a patient's blood through apheresis, genetically reprogramming these cells to recognize and attack tumor cells, and then reintroducing them into the patient. This approach has shown efficacy in treating leukemias and B cell lymphomas by leveraging the body's immune system to target cancer cells.

EsoBiotec is a Belgian biotechnology company dedicated to discovering novel cancer therapies. Its mission is to empower the human body to fight cancer by developing 'in vivo' cell engineering treatments, making cancer therapies more accessible and affordable.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Atekka is an insurance company focused on providing protection against agricultural risks. By integrating technical and technological innovations, Atekka develops customized agricultural insurance products in collaboration with cooperatives and farmers. The company aims to support the agricultural sector by enabling farmers to safeguard their operations from various calamities, thereby enhancing their resilience and sustainability in the face of challenges.

Corteria Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for heart failure subpopulations, particularly focusing on acute decompensated heart failure. The company aims to address unmet medical needs by creating first-in-class drugs that enhance the understanding of disease biology among medical professionals. In addition to heart failure, Corteria also explores treatments for related conditions, such as sarcopenia and obesity, to improve patient outcomes and provide effective solutions for complex health issues. Through its research and development efforts, Corteria Pharmaceuticals seeks to transform the landscape of heart failure treatment.

Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

Telomere Therapeutics is a biotechnology company focused on developing gene therapies that target age-related diseases through the expression of the telomerase gene, specifically TERT. The company's innovative approach utilizes an adenoviral-associated vector to deliver this therapy, aiming to address conditions such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita. By harnessing the potential of telomerase gene therapy, Telomere Therapeutics seeks to provide effective treatment options for prevalent age-related ailments, thereby improving patient outcomes and quality of life.

MiiMOSA is a crowdfunding platform focused on the agriculture and food sectors. It provides an alternative financing solution for project developers seeking quick and straightforward funding from a community of contributors. The platform allows users to create customized fundraising projects while enabling the public to financially support initiatives that resonate with them. In addition to monetary contributions, MiiMOSA offers unique donation options, including products like cheese, yogurt, whiskey, and ice cream, enhancing the engagement between project developers and supporters. This approach fosters a collaborative environment aimed at revitalizing the agriculture industry and promoting sustainable food practices.

Telomere Therapeutics is a biotechnology company focused on developing gene therapies that target age-related diseases through the expression of the telomerase gene, specifically TERT. The company's innovative approach utilizes an adenoviral-associated vector to deliver this therapy, aiming to address conditions such as idiopathic pulmonary fibrosis, aplastic anemia, and dyskeratosis congenita. By harnessing the potential of telomerase gene therapy, Telomere Therapeutics seeks to provide effective treatment options for prevalent age-related ailments, thereby improving patient outcomes and quality of life.

OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Telum Therapeutics is a biotechnology company focused on developing novel treatments for infectious diseases. It specializes in harnessing lytic enzymes derived from bacteriophages, offering an alternative to traditional chemical antibiotics, particularly effective against multi-drug resistant bacteria due to their unique, rapid mode of action and immutable targets.

Gyala Therapeutics specializes in developing innovative CAR-T therapies aimed at treating hematological malignancies. CAR-T (chimeric antigen receptor T cell) therapy involves extracting T lymphocytes from a patient's blood through apheresis, genetically reprogramming these cells to recognize and attack tumor cells, and then reintroducing them into the patient. This approach has shown efficacy in treating leukemias and B cell lymphomas by leveraging the body's immune system to target cancer cells.

Pulmobiotics is a Barcelona-based pre-clinical life sciences company that uses synthetic biology to develop innovative treatments and vaccines for various lung diseases.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.